These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 8763692

  • 21. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.
    Oncogene; 2008 Jan 17; 27(4):506-18. PubMed ID: 17637748
    [Abstract] [Full Text] [Related]

  • 22. Intermittent Complete Androgen Blockade in Metastatic Prostate Cancer.
    Rambeaud J.
    Eur Urol; 1998 Dec 17; 35 Suppl S1():32-36. PubMed ID: 9858850
    [Abstract] [Full Text] [Related]

  • 23. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
    Bruchovsky N, Klotz L, Crook J, Goldenberg SL.
    Cancer; 2007 Mar 01; 109(5):858-67. PubMed ID: 17265527
    [Abstract] [Full Text] [Related]

  • 24. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
    Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS.
    Cancer Res; 1998 Dec 15; 58(24):5718-24. PubMed ID: 9865729
    [Abstract] [Full Text] [Related]

  • 25. Molecular analysis integrating different pathways associated with androgen-independent progression in LuCaP 23.1 xenograft.
    Rocchi P, Muracciole X, Fina F, Mulholland DJ, Karsenty G, Palmari J, Ouafik L, Bladou F, Martin PM.
    Oncogene; 2004 Dec 02; 23(56):9111-9. PubMed ID: 15489889
    [Abstract] [Full Text] [Related]

  • 26. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
    Leon CG, Locke JA, Adomat HH, Etinger SL, Twiddy AL, Neumann RD, Nelson CC, Guns ES, Wasan KM.
    Prostate; 2010 Mar 01; 70(4):390-400. PubMed ID: 19866465
    [Abstract] [Full Text] [Related]

  • 27. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ.
    Cancer Res; 2000 Feb 01; 60(3):741-8. PubMed ID: 10676662
    [Abstract] [Full Text] [Related]

  • 28. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS.
    Cancer Res; 2006 Nov 01; 66(21):10613-20. PubMed ID: 17079486
    [Abstract] [Full Text] [Related]

  • 29. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N, Akakura K, Isaka S, Nakatsu H, Tanaka M, Ito H, Masai M, Chiba Prostate Study Group.
    Urology; 2004 Aug 01; 64(2):341-5. PubMed ID: 15302491
    [Abstract] [Full Text] [Related]

  • 30. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.
    Prostate; 2008 Mar 01; 68(4):453-61. PubMed ID: 18196538
    [Abstract] [Full Text] [Related]

  • 31. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
    Eigl BJ, Eggener SE, Baybik J, Ettinger S, Chi KN, Nelson C, Wang Z, Gleave ME.
    Clin Cancer Res; 2005 Jul 01; 11(13):4905-11. PubMed ID: 16000589
    [Abstract] [Full Text] [Related]

  • 32. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
    Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC.
    Cancer Res; 1999 May 01; 59(9):2136-41. PubMed ID: 10232600
    [Abstract] [Full Text] [Related]

  • 33. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS, Husbeck B, Feldman D, Knox SJ.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):935-40. PubMed ID: 18760546
    [Abstract] [Full Text] [Related]

  • 34. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A.
    Clin Cancer Res; 2003 Oct 01; 9(12):4505-13. PubMed ID: 14555524
    [Abstract] [Full Text] [Related]

  • 35. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM.
    Cancer Res; 1999 May 01; 59(9):2203-9. PubMed ID: 10232609
    [Abstract] [Full Text] [Related]

  • 36. Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?
    Richards A, McGeechan K, Niknam M, Salomon R, Kurek C, Dong Q, Patel MI.
    ANZ J Surg; 2009 Sep 01; 79(9):641-7. PubMed ID: 19895521
    [Abstract] [Full Text] [Related]

  • 37. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
    Debes JD, Comuzzi B, Schmidt LJ, Dehm SM, Culig Z, Tindall DJ.
    Cancer Res; 2005 Jul 01; 65(13):5965-73. PubMed ID: 15994976
    [Abstract] [Full Text] [Related]

  • 38. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
    Miyake H, Nelson C, Rennie PS, Gleave ME.
    Cancer Res; 2000 May 01; 60(9):2547-54. PubMed ID: 10811138
    [Abstract] [Full Text] [Related]

  • 39. The magnitude of early castration-induced primary tumour regression in prostate cancer does not predict clinical outcome.
    Ohlson N, Bergh A, Nygren K, Stattin P, Wikström P.
    Eur Urol; 2006 Apr 01; 49(4):675-83. PubMed ID: 16387414
    [Abstract] [Full Text] [Related]

  • 40. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo.
    Srikanth S, Kraft AS.
    Cancer Res; 1998 Feb 15; 58(4):834-9. PubMed ID: 9485043
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.